
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Rule 13 or 15(d)
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):
October 23, 2019**

CRH MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)

British Columbia, Canada
(State or other jurisdiction
of incorporation)

001-37542
(Commission
File Number)

Not Applicable
(IRS Employer
Identification No.)

**Suite 578 - 999 Canada Place, World Trade Center, Vancouver,
British Columbia, Canada**
(Address of principal executive offices)

V6C 3E1
(Zip Code)

(604) 633-1440
(Registrant's telephone number, including area code)

Not Applicable
(Former name of former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 7.01 REGULATION FD DISCLOSURE

On October 23, 2019, CRH Medical Corporation issued a press release regarding its entrance into a new three year revolving credit facility. A copy of the press release is being furnished herewith as Exhibit 99.1.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

**Exhibit
No.**

Description

[99.1](#) [Press Release issued by CRH Medical Corporation on October 23, 2019](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CRH MEDICAL CORPORATION

(Registrant)

Date: October 23, 2019

By: /s/ Richard Bear

Name: Richard Bear

Title: Chief Financial Officer

CRH Medical Announces New Revolving Credit Facility

VANCOUVER, Oct. 23, 2019 /CNW/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ("CRH" or the "Company") today announced that it has entered into a new, three year revolving credit facility (the "new facility"), which provides up to \$200 million in borrowing capacity, and represents an increase from the company's previous \$100 million facility. The new facility includes a committed \$125 million facility and access to an accordion feature that would increase the amount of credit available to CRH by \$75 million.

The lending syndicate for the new facility is led by JPMorgan Chase Bank, N.A. ("J.P. Morgan") and also includes The Bank of Nova Scotia, U.S. Bank and Wells Fargo.

The new facility reduces the interest rate payable by CRH by as much as 100 bps to LIBOR plus 125 bps, up to LIBOR plus 175 bps, based upon CRH's debt to EBITDA ratio. Other improved terms include a maximum debt to EBITDA ratio of 3x and a minimum interest coverage ratio of 3x.

Richard Bear, Chief Financial Officer of CRH, stated, "We are pleased with this new agreement as it provides access to increased liquidity and financial flexibility while lowering our borrowing costs. We expect the combination of our cash flow, capital structure and liquidity to support future value creation initiatives on behalf of our shareholders."

Tushar Ramani, Chief Executive Officer of CRH, added, "CRH is proud to have secured this important level of funding by some of the highest caliber lenders in the healthcare industry. We appreciate their confidence in our business and look forward to our continued relationship with each of them."

Sebastien Boulanger, Executive Director with J.P. Morgan, stated, "CRH is a leading healthcare services provider. J.P. Morgan is very pleased to lead CRH's new facility and support the company in its next stage of growth. "

About CRH Medical Corporation:

CRH Medical Corporation is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH became a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures in ambulatory surgical centers. To date, CRH has completed 23 anesthesia acquisitions. CRH now serves 52 ambulatory surgical centers in 11 states and performs approximately 333,000 procedures annually. In addition, CRH owns the CRH O'Regan System, a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. CRH distributes the O'Regan System, treatment protocols, operational and marketing

expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves. CRH's O'Regan System is currently used in all 48 lower US states.

View original content:<http://www.prnewswire.com/news-releases/crh-medical-announces-new-revolving-credit-facility-300943499.html>

SOURCE CRH Medical Corporation

View original content:

<http://www.newswire.ca/en/releases/archive/October2019/23/c6002.html>

%CIK: 0001461119

For further information: CRH Medical Corporation, Richard Bear, Chief Financial Officer, 425-658-0151, rbear@crhmedcorp.com; Constantine Davides, CFA, 339-970-2846, constantine.davides@westwicke.com, <http://investors.crhssystem.com/>

CO: CRH Medical Corporation

CNW 08:30e 23-OCT-19